JP2019527037A - がんのための診断及び治療方法 - Google Patents

がんのための診断及び治療方法 Download PDF

Info

Publication number
JP2019527037A
JP2019527037A JP2018564409A JP2018564409A JP2019527037A JP 2019527037 A JP2019527037 A JP 2019527037A JP 2018564409 A JP2018564409 A JP 2018564409A JP 2018564409 A JP2018564409 A JP 2018564409A JP 2019527037 A JP2019527037 A JP 2019527037A
Authority
JP
Japan
Prior art keywords
cancer
patient
methylation
level
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018564409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527037A5 (enExample
Inventor
ロバート エル． ヤウチ，
ロバート エル． ヤウチ，
シアオフェン イエー，
シアオフェン イエー，
トーマス イー． ジャヌアリオ，
トーマス イー． ジャヌアリオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2019527037A publication Critical patent/JP2019527037A/ja
Publication of JP2019527037A5 publication Critical patent/JP2019527037A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018564409A 2016-06-08 2017-06-08 がんのための診断及び治療方法 Pending JP2019527037A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662347436P 2016-06-08 2016-06-08
US62/347,436 2016-06-08
PCT/US2017/036515 WO2017214373A1 (en) 2016-06-08 2017-06-08 Diagnostic and therapeutic methods for cancer

Publications (2)

Publication Number Publication Date
JP2019527037A true JP2019527037A (ja) 2019-09-26
JP2019527037A5 JP2019527037A5 (enExample) 2020-07-27

Family

ID=59325632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018564409A Pending JP2019527037A (ja) 2016-06-08 2017-06-08 がんのための診断及び治療方法

Country Status (5)

Country Link
US (2) US20200129519A1 (enExample)
EP (1) EP3469099A1 (enExample)
JP (1) JP2019527037A (enExample)
CN (1) CN109312407A (enExample)
WO (1) WO2017214373A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505426A (ja) * 2017-02-02 2020-02-20 エピザイム，インコーポレイティド 癌処置様式
JP2023082308A (ja) * 2021-12-02 2023-06-14 国立大学法人 長崎大学 スクリーニング方法、環状ペプチドおよびこれを含む癌細胞増殖抑制剤
WO2024111743A1 (ko) * 2022-11-22 2024-05-30 주식회사 네오나 Gas5 억제제 및 smarca4 억제제를 유효성분으로 포함하는 간암 예방 또는 치료용 약학 조성물

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX376008B (es) 2012-10-15 2025-03-07 Epizyme Inc Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2018002344A (es) 2015-08-24 2018-07-06 Epizyme Inc Metodo para tratar el cancer.
AU2018227774A1 (en) * 2017-02-28 2019-09-19 Epizyme, Inc. Inhibition of SMARCA2 for treatment of cancer
US20220154295A1 (en) * 2019-03-27 2022-05-19 The Johns Hopkins University Methods and materials for assessing and treating cancer
CN111849866B (zh) * 2020-07-15 2022-06-24 华南农业大学 H3K27me3调控FoxO1基因表达在猪卵巢颗粒细胞中的应用
CN112904006B (zh) * 2021-01-28 2022-12-27 中山大学 一种乳腺癌预后预测分子标志物及其应用
DE102022112378B4 (de) * 2022-05-17 2024-02-15 Abberior Instruments Gmbh Verfahren, lichtmikroskop und computerprogramm zur bestimmung eines referenzzeitpunktes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018529698A (ja) * 2015-09-25 2018-10-11 エピザイム，インコーポレイティド Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法
JP2018530527A (ja) * 2015-08-27 2018-10-18 イーライ リリー アンド カンパニー Ｅｚｈ２の阻害剤
JP2019508406A (ja) * 2016-02-08 2019-03-28 エピザイム，インコーポレイティド 癌を処置する方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE135373T1 (de) 1989-09-08 1996-03-15 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
MX9700535A (es) 1994-07-21 1997-04-30 Akzo Nobel Nv Formulaciones de peroxido de cetona ciclico.
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK0980244T3 (da) 1997-05-06 2003-09-29 Wyeth Corp Anvendelse af quinazoline forbindelser til behandling af polycystisk nyresygdom
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CA2306155A1 (en) 1997-11-06 1999-05-20 Philip Frost Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
EP2694677A2 (en) * 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
MX376008B (es) * 2012-10-15 2025-03-07 Epizyme Inc Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
WO2014176047A1 (en) * 2013-04-25 2014-10-30 Novartis Ag Markers for ezh2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018530527A (ja) * 2015-08-27 2018-10-18 イーライ リリー アンド カンパニー Ｅｚｈ２の阻害剤
JP2018529698A (ja) * 2015-09-25 2018-10-11 エピザイム，インコーポレイティド Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法
JP2019508406A (ja) * 2016-02-08 2019-03-28 エピザイム，インコーポレイティド 癌を処置する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. 75(18), JPN6021028203, 2015, pages 3865, ISSN: 0004726894 *
INT. J. BIOL. SCI., vol. 8(1), JPN6021028202, 2012, pages 59 - 65, ISSN: 0004726895 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505426A (ja) * 2017-02-02 2020-02-20 エピザイム，インコーポレイティド 癌処置様式
JP7324144B2 (ja) 2017-02-02 2023-08-09 エピザイム，インコーポレイティド 癌処置様式
JP2023082308A (ja) * 2021-12-02 2023-06-14 国立大学法人 長崎大学 スクリーニング方法、環状ペプチドおよびこれを含む癌細胞増殖抑制剤
WO2024111743A1 (ko) * 2022-11-22 2024-05-30 주식회사 네오나 Gas5 억제제 및 smarca4 억제제를 유효성분으로 포함하는 간암 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
CN109312407A (zh) 2019-02-05
WO2017214373A1 (en) 2017-12-14
EP3469099A1 (en) 2019-04-17
WO2017214373A8 (en) 2018-03-01
US20200129519A1 (en) 2020-04-30
US20210338684A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
US20240011098A1 (en) Diagnostic and therapeutic methods for cancer
JP7530829B2 (ja) がんの診断及び治療方法
US20210338684A1 (en) Diagnostic and therapeutic methods for cancer
ES2789500T5 (es) Procedimientos terapéuticos y de diagnóstico para el cáncer
US20190032150A1 (en) Diagnostic and therapeutic methods for cancer
JP2018508183A (ja) 化学療法耐性癌を治療及び診断する組成物及び方法
JP2017523776A (ja) 膠芽腫の診断方法及びその治療用組成物
TW202023617A (zh) 膀胱癌之治療及診斷方法
US20240060135A1 (en) Therapeutic and diagnostic methods for cancer
JP2015525563A (ja) Ｒａｃ変異体を含む組成物、及びその使用方法
JP2025539129A (ja) 改善された癌処置のための組成物及び方法
US20170202867A1 (en) Methods of inhibiting cancer stem cells with hmga1 inhibitors
HK40003987A (zh) 用於癌症的诊断和治疗方法
HK40032701A (en) Diagnostic and therapeutic methods for cancer
HK40032701B (zh) 用於癌症的诊断和治疗方法
HK40002144A (en) Diagnostic and therapeutic methods for cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220315